Analgesia News and Research

RSS

Botox can have unsuspected 'systemic' effects on muscles

Botulinum neurotoxin type A—better known as Botox—has previously unsuspected 'systemic' effects on muscles other than the ones it's injected into, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

23 Dec 2011

ASCs need to develop policies for management of malignant hyperthermia

As the number of surgical procedures performed outside hospitals continues to increase, ambulatory surgical centers (ASCs) need to develop policies for managing malignant hyperthermia—a rare but serious reaction to anesthetics, according to an expert panel report in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

23 Dec 2011

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

19 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

Positive results from Aestus' ATx08-001 Phase II study on post-herpetic neuralgia

Aestus Therapeutics, Inc. today reported positive results from a Phase II clinical study evaluating the efficacy of its novel neuropathic pain therapeutic, ATx08-001, in the treatment of post-herpetic neuralgia.

14 Dec 2011

ETView files VIVASIGHT DL 510(k) Pre-Marketing Notification Application with FDA

ETView (TASE: ETVW) today announced that the company has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration.

12 Dec 2011

No variation in mortality by timing of operation

The timing of surgical procedures—afternoon versus morning or Friday versus Monday—doesn't affect the risk of death after surgery, concludes a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Nov 2011

Anesthesia drug shortages can have devastating impact on patient care

The United States is facing ongoing shortages of several critical anesthesia medications—shortages with potentially serious effects on patient care and safety, according to a special article in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Nov 2011

Anesthesia & Analgesia introduces new electronic edition

The editors of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), are pleased to announce the launch of their new Anesthesia & Analgesia for the iPad app.

24 Nov 2011

Pacira prices public offering of 7,000,000 shares of common stock

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share.

16 Nov 2011

Researchers explore how design of chronic and acute pain trials might be improved

For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.

15 Nov 2011

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

HRM curve analysis identifies patients at risk of MH

A new DNA test may make it much simpler to identify patients at risk of malignant hyperthermia (MH)—a rare but life-threatening complication of exposure to common anesthetics reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

2 Nov 2011

SmartTots sets agenda for research on anesthetic safety in children

A special section of the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS), presents new research, updates, and commentaries about possible toxic effects of anesthetics and sedatives in infants and young children. The IARS is a key partner in the SmartTots initiative, dedicated to finding scientific answers to these urgent public health concerns.

2 Nov 2011

Heat, extreme exercise or febrile illness may also trigger MH

Malignant hyperthermia (MH) is a potentially life-threatening inherited disorder of muscle. Patients who are at risk for MH usually have no outward signs of muscle problems. However, when exposed to certain commonly used general anesthetics they may develop very high body temperature, increased heart rate and muscle breakdown. If not recognized and treated promptly MH may be fatal.

1 Nov 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

FDA approves Pacira's EXPAREL for postsurgical pain management

Pacira Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved EXPAREL 1.3% for administration into the surgical site to produce postsurgical analgesia.

31 Oct 2011

Multimodal analgesia is used less than 25% of the time prior to surgery

Many surgical patients are concerned about the level of pain they will experience. In a new study presented at ANESTHESIOLOGY 2011, researchers from Thomas Jefferson University identified that multimodal analgesia, a combination of pain medication and therapeutic measures to improve pain control, is used less than 25 percent of the time prior to surgery.

19 Oct 2011

Researchers control itch without dulling morphine's pain-killing effects

Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.

14 Oct 2011